Positive Phase III data for roflumilast cream in plaque psoriasis presented at conference

In the DERMIS-1 and DERMIS-2 studies, Investigator Global Assessment success at week 8 (primary endpoint) was higher with roflumilast 0.3% cream than with vehicle (42.4% v 6.1% in DERMIS-1 and 37.5% v 6.9% in DERMIS-2; p<0.001 for both).

Source:

Biospace Inc.